Ozmosi | Perifosine Drug Profile

Product Description

Mechanisms of Action: Akt Inhibitor, PI3K Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AEterna Zentaris
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Multiple Myeloma|Colorectal Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT00847366	Perifosine 534	N/A	Completed	Breast Cancer\|Sarcoma\|Non-Small-Cell Lung Cancer\|Multiple Myeloma	2012-12-01		2025-02-07	Primary Endpoints\|Treatments
NCT02238496	AAAM3801	P1	Completed	Glioblastoma\|Astrocytoma\|Oligodendroglioma\|Brain Cancer	2017-10-27	88%	2023-05-26	Primary Endpoints\|Treatments
NCT00776867	NCT00776867	P1	Completed	Oncology Solid Tumor Unspecified	2017-07-01		2019-03-18
NCT01049841	NCT01049841	P1	Completed	Oncology Solid Tumor Unspecified	2017-03-01		2025-08-27	Primary Endpoints\|Treatments
JapicCTI-132130	JapicCTI-132130	P1	Completed	Neuroblastoma	2015-11-01
NCT01224730	Protocol 147	P1	Completed	Myocardial Infarction\|Angina, Stable\|Angina, Unstable\|Heart Failure, Acute\|Hepatitis B, Chronic\|Torsades de Pointes\|HIV Infections\|Hypertrophy, Left Ventricular\|Pregnancy Outcomes\|Contraception\|Heart Failure, Chronic\|Neuromyelitis Optica\|Hypokalemia\|Angina Pectoris\|Hepatitis C, Chronic\|Surgical Wound Infection	2013-11-04		2019-03-19	Treatments
JapicCTI-121748	JapicCTI-121748	P1	Terminated	Multiple Myeloma	2012-12-31
NCT00415064	Perifosine 127	P1	Completed	Multiple Myeloma	2012-07-01		2025-08-27	Primary Endpoints\|Treatments
NCT00301938	NCI-2009-00149	P1	Completed	Myelodysplastic-Myeloproliferative Diseases\|Chronic Myelomonocytic Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myelodysplastic Syndrome\|Adult T-Cell Leukemia-Lymphoma\|Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Acute Megakaryoblastic Leukemia\|Acute Promyelocytic Leukemia\|Preleukemia\|Chronic Lymphoid Leukemia\|Acute Monocytic Leukemia\|Blast Crisis\|Myeloid, Accelerated Leukemia\|Acute Lymphoid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Myeloproliferative Disorders\|Acute Erythroblastic Leukemia\|Acute Myelomonocytic Leukemia	2012-05-01		2019-03-21
NCT00431054	Pharmacodynamic Trial	P1	Completed	Ovarian Cancer	2012-05-01		2019-03-21	Treatments
NCT00398814	Perifosine 124	P1	Completed	Renal Cell Carcinoma\|Kidney Cancer	2011-09-01		2019-03-21	Treatments
NCT01048580	Perifosine 141	P1	Completed	Colorectal Cancer	2011-05-01		2019-03-19	Treatments
NCT00590954	NCT00590954	P2	Completed	Glioma\|Brain Cancer	2019-11-11		2025-08-27	Primary Endpoints\|Treatments
NCT01051557	NCI-2011-01409	P2	Completed	Astrocytoma\|Glioblastoma\|Oligodendroglioma\|Gliosarcoma	2018-11-16		2021-07-20
JapicCTI-132287	JapicCTI-132287	P2	Completed	Ovarian Cancer\|Cervical Cancer	2015-11-30
JapicCTI-111712	JapicCTI-111712	P2	Terminated	Colorectal Cancer	2013-07-31
NCT00873457	Pro00015060	P2	Completed	Lymphocytic Chronic B-Cell Leukemia\|Lymphoma, B-Cell\|Chronic Lymphoid Leukemia	2011-10-01		2019-03-18	Treatments
NCT00398710	Perifosine 221	P2	Completed	Waldenstrom Macroglobulinemia	2011-08-01		2019-03-21	Treatments
NCT00389077	Perifosine 207	P2	Completed	Lymphoma	2011-07-01		2019-03-21	Treatments
NCT00498966	Perifosine 231	P2	Completed	Kidney Cancer	2011-07-01		2019-03-21	Treatments
NCT00401388	Perifosine 214	P2	Completed	Chondrosarcoma\|Alveolar Soft Part Sarcoma	2011-01-01		2019-03-22	Treatments
NCT00398879	Perifosine 211	P2	Completed	Colorectal Cancer	2010-12-01		2019-03-21	Treatments
2010-018893-19	2010-018893-19	P3	Terminated	Multiple Myeloma	2013-03-11		2022-03-13	Treatments
NCT01002248	Perifosine 339	P3	Terminated	Multiple Myeloma	2013-03-01		2025-08-27	Primary Endpoints\|Treatments
NCT01097018	X-PECT	P3	Completed	Colorectal Cancer	2012-04-01		2019-03-19	Treatments

Recent News Events

Date	Type	Title
03/01/2024	PubMed	Neuroprotective effects of Rehmannia glutinosa polysaccharide on chronic constant light (CCL)-induced oxidative stress and autophagic cell death via the AKT/mTOR pathway in mouse hippocampus and HT-22 cells.
02/01/2024	PubMed	Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells.
01/15/2024	PubMed	ROS/mtROS promotes TNTs formation via the PI3K/AKT/mTOR pathway to protect against mitochondrial damages in glial cells induced by engineered nanomaterials.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Perifosine

Alternative Names: perifosine Clinical Status: Inactive Latest Update: 2024-03-01 Latest Update Note: PubMed Publication